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ABSTRACT 
Introduction 
AHSG, a serum glycoprotein with recognized anti-calcification activity, has also been suggested to modulate 
both bone formation and resorption. Though the bulk of AHSG is mostly synthesized in the liver, it has been 
claimed that also bone cells might produce it. However, it remains to be definitively proven the extent of 
the bone AHSG production and the potential controlling factors.  
A relevant number of studies support the notion that FGF23, a bone-derived hormone, not only regulates 
the most important mineral metabolism (MM) related factors (phosphate, parathyroid hormone, vitamin D, 
etc), but might be also involved in cardiovascular (CV) outcome , both in chronic kidney disease (CKD) 
patients and in the general population. Furthermore, in addition to some direct autocrine and paracrine 
effects in bone, FGF23 has been suggested to interact with AHSG. 
In this study we investigated if AHSG is really produced by bone cells, and if its bone production is related 
and/or controlled by FGF23 , using cultured bone cells, according to a new method recently published by 
our group. 
Results 
Our data show that AHSG is consistently produced in osteocytes and to a far lesser extent in osteoblasts. 
Both FGF23 addition to the culture medium and its over-expression in osteocytes were associated with a 
consistent increase of both AHSG mRNA and protein, while FGF23 silencing was followed by opposite 
effects. Though most of these results were largely affected by the blockage of FGF23 receptors, the role of 
these receptors in the different experimental sets is still not completely clarified. In addition, we found that 
FGF23 and AHSG proteins co-localized both in cytoplasm and nucleus, which suggests a possible reciprocal 
interactivity. 
Conclusions 
Our data not only confirm that AHSG is produced in bone, mainly in osteocytes, but show for the first time 
that its production is modulated by FGF23. Since both proteins play important roles in the bone and 
cardiovascular pathology, these results add new pieces to the puzzling relationship between bone and 
vascular pathology, in particular in CKD patients, prompting future investigations in this field. 
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1.INTRODUCTION 
AHSG (alpha2-HS-glycoprotein), a reverse acute phase serum glycoprotein (MW 52 kDa), belonging to the 
family of the type 3 cystatin proteins, was first described by Pedersen more than 7 decades ago [1]. It has 
long been known that AHSG, thanks to its exceedingly high content in acidic amino-acids, is characterized by 
particularly high mineral affinity and, in addition to its circulating pool, is consistently represented in the 
mineralized bone matrix [2,3] and in ectopic calcifications [4], where it mainly acts as an anti-calcification 
factor [5,6]. Furthermore, It is known that AHSG, which presents homology 1 domain with TGF-β- receptor 
II, has been demonstrated in experimental studies to modulate osteogenesis TGF-β-mediated [7]. 
Overall, much experimental evidence has demonstrated that AHSG, which constitutes 25% of non-
collagenous proteins in bone, could efficiently inhibit mineralization and control both bone formation and 
resorption [8-9]. Since the bulk of circulating AHSG is mostly synthesized in the liver, it was initially assumed 
that the protein in the bone was mainly, if not exclusively, derived from the circulating pool [10,11], though 
a subsequent study suggested that osteoblasts (Ob) express AHSG mRNA and protein and that at least part 
of AHSG present in bone is derived from bone cells [12,13]. However, the real extent and the potential 
controlling factors on the possible AHSG production by bone cells is still not fully defined.  
Recently, a significant number of studies have shown that FGF23, a 32 kDa protein synthesized by bone cells 
(osteoblasts/osteocytes), is a bone-derived hormone mainly devoted to regulate the most important 
mineral metabolism (MM) related factors (phosphate, parathyroid hormone, vitamin D, etc) [14, 15, 16]. 
The main recognized stimuli for FGF23 production are  high phosphorus intake/levels and/or vitamin D 
activity [17]. Its main effects are mediated by high-affinity binding to the FGF-ƌeĐeptoƌ/α-Klotho complex 
and translate into inhibition of phosphate renal tubular transport, calcitriol levels (by both inhibition of 
synthesis and increase of VitD catabolism) and reduction in PTH secretion [17, 18, 19]. 
Furthermore, both experimental and clinical studies suggest that, in addition to the well known MM related 
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effects, high FGF23 levels could be related to poor cardiovascular (CV) outcomes, both in chronic kidney 
disease (CKD) patients and in the general population[20]. Moreover, FGF23 can also have direct autocrine 
and paracrine effects in bone which could be in some way linked to AHSG production itself. Furthermore 
some preliminary evidence suggests that FGF23 and AHSG might interact also at the vascular level, with a 
potential fall-out on the vascular calcification process, particularly in CKD [13, 21]. 
Finally, osteocytes (Os) have been increasingly recognized as the central cells in the production of the main 
bone derived factors acting either as hormonal substance and/or autocrine factors regulating bone 
metabolism itself [22, 23]. We recently described a new efficient method for the in vitro production of well- 
functioning and characterized Os, which clearly produce both sclerostin and FGF23 [24, 25, 26]. 
On the basis of these considerations, we used the Os in vitro system already described in our previous study 
to investigate: if AHSG is really produced by Os, and if its secretion, if any, could be in some way related to 
and/or controlled by FGF23. 
 
2.RESULTS 
2.1.FGF23 expression in mice bone tissue and in cultured Ob and Os.  
Immunochemistry (IHC) performed on tibial bone of Balb/c mice shows that FGF23 was highly expressed in 
Os (Fig.1.A). On the other hand, an only marginal immunostaining was evident in the mature osteoblasts 
lining the bone marrow space where highly positive bone cells are evident (Fig.1.B). The lower 
magnification figure gives information about the analysed tissue area (Fig.1.C). 
In ATRA-cultured cells, FGF23 expression progressively increased during Os maturation as assessed by both 
IS and WB (Fig.1.D-G). Quantitative Real Time RT-PCR (qRT PCR) also confirmed a significant increase of 
FGF23 mRNA expression in Os (Fig.1.H). On the contrary, the levels of FGF23 protein (data not shown) and 
mRNA (Fig.1.I) progressively decreased in Ob and were consistently lower than in Os at the time 12 (Fig.1.L). 
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Figure 1.  
A, B. Arrows show immunostaining of FGF23 in Os and Ob in mouse tibial bone. Scale bars A, B: 50µm. 
C. Low magnification image of the areas analyzed: Os (red line) and Ob (blue line). Scale bar: 100µm.  
D, E, F. FGF23 expression, visualized by rhodamine IS in Os after 4, 8, 12 days in culture. Scale bars: 100µm. 
G. FGF23 WB in Os after 4, 8, 12 days in culture. n=3-7/group. Cofilin (bottom of the gel) acted as a loading 
control. 
H. qRT PCR of FGF23 mRNA expression in Os. Bars are means ±SD; n=4-5/group. 
I. qRT PCR of FGF23 mRNA expression in Ob. Bars are means ±SD; n=3-5/group. 
L. FGF23 mRNA expression in Ob and in Os after 12 days in culture. 
Asterisks indicate significant differences versus Os or Ob T4 (ctrl) (H,I) or Ob T12 (L): **=p<0.01, 
***=p<0.001 by ANOVA.  
 
2.2.AHSG expression in mice bone tissue and in cultured Ob and Os.  
Os of mice tibial bone highly expressed AHSG protein as assessed by IHC in Os (Fig.2.A) and marginally in Ob 
(Fig.2.B). The lower magnification gives an idea of the tissue areas analysed (Fig.2.C). 
AHSG expression increased in a time-dependent way in cultured Os as shown by IS (Fig.2.D, E, F), WB 
(Fig.2.G) and qRT PCR (Fig.2.H). On the other hand, AHSG protein (data not shown) and mRNA expression 
progressively decreased in Ob (Fig.2.I). Overall, AHSG expression was by far lower in Ob than Os and almost 
undetectable in the former cells after 12 days in culture (Fig.2.L). 
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Figure 2.  
A, B. Arrows show AHSG immunostaining in Os and Ob in mouse tibial bone. Scale bars A, B: 50µm. 
C. Low magnification image of the areas analyzed: Os (red line) and Ob (blue line). Scale bar: 100 µm.  
D, E, F. Rhodamine IS of AHSG at 4, 8, 12 days in Os. Scale bars: 100µm. 
G. AHSG WB in Os after 4, 8, 12 days in culture. n=3-7/group. Cofilin (bottom of the gel) acted as a loading 
control. 
H. qRT PCR of AHSG mRNA expression in Os. Bars are means ±SD; n=4-5/group. 
I. qRT PCR of AHSG mRNA expression in Ob. Bars are means ±SD; n=3-5/group. 
L. AHSG mRNA expression at 12 days in Ob and in Os. 
Asterisks indicate significant differences versus Os or Ob T4 (ctrl)(H, I) or Ob T12(L): **=p<0.01, 
***=p<0.001 by ANOVA.  
 
2.3.Release of AHSG and FGF23 protein in the medium of cultured Ob and Os 
FGF23 released in the cell-culture medium progressively increased over time in Os whereas in Ob the 
observed release was lower and stable (Fig.3.A). Quantitative analysis of AHSG by ELISA showed a far 
greater secretion of the protein by Os as compared to the minimal amount produced by Ob (Fig.3.B). 
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Figure 3. 
A. Cultured medium harvested after Ob and Os were cultured for 4, 8, 12 days for measurements of FGF23 
protein content, assessed by ELISA. Bars are means ±SD; n=3/group. 
B. Cultured medium harvested after Ob and Os were cultured for 4, 8, 12 days for measurements of AHSG 
protein content, assessed by ELISA. Bars are means ±SD; n=3/group. 
Data were normalized by Janus Green Nuclear Marker. Asterisks indicate significant differences versus Os 
T4 (ctrl): *=p<0.05, **=p<0.01 by ANOVA. 
 
2.4.Interactions between AHSG and FGF23 
In order to investigate the possibility that FGF23 and AHSG might interact with one other, we focussed our 
studies on Os cells since these cells maximally express these proteins from T4 onward, where T4 represents 
the beginning of the differential expression of the two proteins of interested. 
2.4.1.Reciprocal effects of the addition of FGF23 or AHSG 
mRNA expression of both FGF23 and AHSG significantly increased 24 hours after the addition of 
recombinant FGF23. On the contrary, AHSG addition did not affect the expression of either of the two 
(Fig.4.A, B). 
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Figure 4.  
A. Changes of AHSG mRNA expression 24 hours after the addition of either FGF23 or AHSG to T4 Os. Bars 
are means ±SD; n=3-4/group. 
B. Changes of FGF23 mRNA expression 24 hours after the addition of either FGF23 or AHSG to T4 Os. 
Bars are means ±SD; n=3/group. 
Asterisks indicate significant differences versus Os T4 (ctrl): *=p<0.05 by ANOVA test. 
 
2.4.2.Effects of recombinant FGF23 addition on AHSG expression at different culture times 
In order to explore at which time in culture the FGF23 stimulatory action on AHSG was maximal, we 
evaluated the changes of AHSG mRNA expression after FGF23 addition for 24 hours in cells cultured for 4, 8, 
12 days. AHSG mRNA expression was confirmed to increase with the advancing of time in culture (Fig.5.A). 
However, FGF23 addition seemed to significantly affect AHSG mRNA expression only at day 4. These data 
were also confirmed by both the protein expression (Fig.5.B, C) and qualitative WB (Fig.5.D). Moreover, a 
very evident more elongated shape of the Os treated with FGF23 was observed (Fig.5.E, F). In contrast, no 
difference in cell morphology was observed in the cells treated with AHSG (data not shown). 
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Figure 5. 
A. AHSG mRNA expression in Os cultured for 4, 8, 12 days in either control conditions or following FGF23 
treatment. Bars are means ±SD; n=3-4/group. 
B, C. Immunofluorescence of AHSG at T4 in control (B) and in FGF23-treated (C) Os. Scale bars: 100µm. 
D. WB analysis of AHSG at T4 in control and in FGF23-treated Os; n=3/group. Cofilin (bottom of the gel) 
acted as a loading control. 
E, F. Light microscopy in control (E) and FGF23-treated (F) T4 Os. Scale bars: 100µm. 
Asterisks indicate significant differences versus Os T4 (ctrl): **=p<0.01 by ANOVA .  
 
2.4.3.Effect of FGF23 gene overexpression on AHSG expression 
To assess if not only the addition but also FGF23 overexpression could affect the AHSG production, we 
transfected T4 Os with mouse cDNA FGF23. Transfection induced a more than tenfold increase in FGF23 
mRNA (Fig.6.A) which was associated with a more than doubling of AHSG mRNA levels after 48 hours (Fig. 
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6. B). Immunofluorescence (Fig.6.C, D) and WB (Fig.6.E) confirmed an increase also of the AHSG protein 
levels. Consistent with findings reported above, found a similar, but more evident elongated shape in the Os 
overexpressing FGF23 (Fig.6.F, G).  
 
Figure 6. 
A. qRT PCR of FGF23 mRNA in control and FGF23 overexpressing Os at 48 hours. Bars are means ±SD; 
n=4/group. 
B. qRT PCR of AHSG mRNA in control and FGF23 overexpressing Os at 48 hours. Bars are means ±SD; 
n=4/group. 
C, D. Immunofluorescent detection of AHSG protein at 48 hours in control (C) and FGF23 overexpressing (D) 
Os. Scale bars: 100µm. 
E. AHSG WB analysis in control and FGF23 overexpressing Os at 48 hours. n=3/group. Cofilin (bottom of the 
gel) acted as a loading control. 
F, G. Light microscopy of control (F) and FGF23 overexpressing Os at 48 hours (G). Scale bars: 100µm. 
Asterisks indicate significant differences versus Os T4 (ctrl): *=p<0.05; **=p<0.01 StudeŶt’s t-test 
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2.4.4.Effects of FGF23 gene silencing on AHSG expression 
To test the hypothesis that FGF23 reduction might also affect AHSG levels, we transfected T4 Os with FGF23 
specific siRNA.  
qRT PCR confirmed an almost complete FGF23 mRNA silencing at 48 hours (Fig.7.A), and a relatively marked 
reduction of both AHSG mRNA (Fig.7.B) and protein (Fig.7.C, D) in Os. Qualitative WB analyses at 48 hours 
confirmed AHSG protein abolition in silenced Os (Fig.7.E). 
 
Figure 7.  
A. qRT PCR of FGF23 mRNA in control and silenced Os at 48 hours after FGF23 gene silencing. Bars are 
means ±SD; n=3/group. 
B. qRT PCR of FGF23 mRNA in control and silenced Os at 48 hours after FGF23 gene silencing. Bars are 
means ±SD; n=3/group. 
C, D. Immunofluorescent detection of AHSG protein in control (C) and in FGF23 mRNA silenced Os (D) 48 
hours after gene silencing. Scale bars C, D: 100µm. 
E. AHSG WB in T4 control and FGF23 mRNA silenced Os; n=3/group. Cofilin (bottom of the gel) acted as a 
loading control. 
Asterisks indicate significant differences versus Os T4 (ctrl): **=p<0.01 by StudeŶt’s t-test.  
 
 
2.5.FGF receptors (FGFRs) expression and effects of their inhibitor on FGF23  
12 
 
2.5.1.FGFR expression in cultured Os  
To investigate if the stimulatory effects of either FGF23 addition or overexpression on AHSG production 
were mediated by FGFR, we explored first whether our cultured cells expressed the known FGFRs. Indeed, 
FGFR1, FGFR2, FGFR3 and FGFR4, evaluated by semi quantitative RT-PCR (Fig.8.A) were all clearly present in 
cultured Os, though the FGFR1 appeared more brightly expressed than the others.  
2.5.2.Influence of FGFR inhibition on FGF23 expression  
Then, we explored whether blocking FGFR by FIIN1 (a global and irreversible FGFRs blocker) affects the 
FGF23 auto-stimulatory effects secondary to the addition of FGF23 to the culture medium. Addition of FIIN1 
alone to Os did not induce any change of FGF23 mRNA and protein expression levels (Fig.8.B, C). 
Furthermore, the simultaneous addition of FIIN1 and recombinant FGF23 completely abolished the auto-
stimulatory effects of the external FGF23 addition (Fig.8.B, C). 
 
Figure 8.  
A. FGFRs expression in T4 Os, examined by semi-quantitative PCR. 
B. qRT PCR of FGF23 mRNA in Os T4 in ctrl, after FGF23 addition, after FGFRs block (FIIN1) addition and 
after addition of both FGF23 and FGFR blockers. Bars are means ±SD; n=3-5/group. 
C. WB analyses of the same (B) experiment n=3-4/group. Cofilin (bottom of the gel) acted as a loading 
control. 
Asterisks indicate significant differences versus Os T4 (ctrl): **=p<0.01 by ANOVA. 
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2.5.3.Influence of FGFRs inhibition on AHSG expression  
Next we explored the effects of FGFRs blockade on the AHSG stimulating effects by FGF23 addition. As in 
the previous experiments, FGF23 addition confirmed its stimulating effects on AHSG mRNA expression 
(Fig.9.A). Unexpectedly, FGFRs block alone resulted in a stimulating effect on AHSG mRNA (Fig.9.A), 
confirmed by a parallel increase of protein expression, detected by qualitative WB (Fig.9.B). When 
recombinant FGF23 was added in the presence of FGFRs block to the cultured Os, a further significant 
increase in mRNA and, to a lesser extent of the protein production were observed (Fig9.B). 
 
 
Figure 9.  
A. qRT PCR of AHSG mRNA in Os T4 in ctrl, after FGF23 addition, after FGFRs block (FIIN1) addition and after 
both FGF23 and FGFRs block addition. Bars are means ±SD; n=4-5/group. 
B. WB analyses of the same (A) experiment; n=3-5/group. Cofilin (bottom of the gel) acted as a loading 
control. 
Asterisks indicate significant differences versus Os T4 (ctrl): *=p<0.05, **=p<0.01. Triangles significant 
differences versus FGFRs blocked plus FGF23 treated Os: ▲= p<0.05 by ANOVA.  
 
2.6.Effects of FGF23 overexpression with the contemporary FGFRs block, on AHSG production  
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We then tested the effects of FGF23 overexpression in the presence of FIIN1. The FGF23 overexpression 
reconfirmed a stimulatory effect on both AHSG mRNA and protein production (Fig.10.A, B). After FGFRs 
blockade alone, a striking increase of AHSG mRNA and protein was observed. In contrast, FGF23 
overexpression in the presence of FGFRs block was not additive to the AHSG stimulatory effects (Fig.10.A, 
B). 
 
Figure 10.  
A. qRT PCR of AHSG mRNA in control, in FGF23 overexpressing, in FGFR blocked and in both FGFR blocked 
plus FGF23 overexpressing. Bars are means ±SD; n=3-4/group.  
B. WB analyses of the same experiment (A); n=3/group. Cofilin (bottom of the gel) acted as a loading 
control. 
Asterisks indicate significant differences versus Os T4 (ctrl): *=p<0.05, **=p<0.01 by ANOVA. 
 
2.7. AHSG promoter gene activation during FGF23 overexpression 
To test if the effects of FGF23 overexpression are dependent on genomic effects, we assessed the changes 
of AHSG promoter gene luciferase activity. FGF23 overexpression translated into a stimulatory effect on 
AHSG promoter gene, which was consistently unchanged over the 48 hour observation time. At variance, 
the FGFRs block resulted in an even more marked, though less persistent, stimulatory effect on AHSG 
promoter gene. FGF23 overexpression in the presence of FGFRs blockade activated AHSG promoter, an 
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effect which persisted over 48 hours (data not shown) but that was not additive to the AHSG stimulatory 
effects (Fig.11.A, B). 
We also explored whether FGF23 was present either in the cytoplasm and/or the nucleus. As shown by 
qualitative WB analysis, FGF23 protein was present in the cytoplasmic and, to a lesser extent, in the nuclear 
compartments (Fig.11.C). 
 
Figure 11. 
A, B. Activation of AHSG promoter detected by secreted Gaussia Luciferase at 24, 36 hours after FGF23 
overexpression, after addition of FGFR blocker and both FGF23 overexpression and FGFR blocker. Bars are 
means ±SD; n=3/group. 
C. WB analysis of Os T4 detected the FGF23 band in both fractions, the nucleus and the cytoplasm; 
n=3/group. Cofilin (bottom of the gel) acted as a loading control. 
Asterisks indicate significant differences versus Os T4 (ctrl): *=p<0.05, **=p<0.01 by ANOVA. 
 
2.8.Cell colocalization and protein interaction of AHSG and FGF23 
We first detected the colocalization of AHSG and FGF23 by double immunofluorescence staining , which was 
clearly evident in our cells (Fig.12.A, B, C). In order to verify the proximity of these two proteins, we 
performed Duolink assay which provides signal interaction of proteins which must be within 0 to 40nm 
distance. Results obtained using this approach show that AHSG and FGF23 appeared very close to each 
other. AHSG and FGF23 interaction was also determined and quantified in both nucleus and in cytoplasm of 
Os T4 cells. AHSG/FGF23 interaction was evident both in the cytoplasm and, to a lesser extent, in the 
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nuclear space (Fig.13.A-D) 
 
Figure 12.  
Immunofluorescence of AHSG (A), FGF23 (B) and merge (C) shows their colocalization. Scale bars: 50µm.  
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Figure 13.  
A, B. Cell localization of AHSG/FGF23 interactions detected by Duolink in situ experiment in the nucleus and 
in the cytoplasm of Os T4 (A). The negative control exhibits only nuclear DAPI staining showing the 
presence of cells (B). Scale bars: 50µm. 
C. Transformation in white image for quantification with IMAGE J program. Red line indicates total surface 
area, blue line indicates the nuclear space. Scale bars: 50µm. 
D. Quantification of AHSG/FGF23 interactions by following calculation: whole surface area - nucleus area; 
n=13 cells.  
Asterisks indicate significant differences **=p<0.01 by StudeŶt’s t-test. 
 
3.DISCUSSION 
Among its multifold roles, the bone is the subject and the object of an intense hormonal and metabolic 
control, being involved not only in its long time recognized canonical functions (mechanical, protective, 
hematopoietic, MM) but also in the more recently described interactions with the CV system [22, 27, 28]. 
All these functions rely on a complicated system which recognizes the Os as the central key player, since this 
cell, through its multi-branched canaliculi web, controls the Ob and osteoclast (Oc) functions by juxta and 
paracrine mechanisms, via the production of a great number of hormonal factors, namely FGF23, 
osteocalcin, osteoprotegerin, sclerostin, Dickkopf-related protein 1(DKK1), bone morphogenic proteins 2-7 
(BMP2-7), etc., leading to metabolic effects on many different organs (kidney, brain, liver, pancreas, heart, 
vascular system, etc.) [29, 30]. 
In these dynamic systems we focused our attention on two proteins which have been believed to play roles 
in both the bone and vascular systems, namely FGF23 and AHSG, the first being a well-recognized bone-
derived protein and the second being produced mainly by the liver, though it has been suggested that it is 
produced by bone cells too. We explored this issue using our recently described method for in vitro 
culturing of stable Os cells [24]. We utilized the MC3T3-E1 cell line to obtain Os in an easy and highly 
reproducible way, to have the opportunity of culturing cells at different stages of maturation (from pre-
osteoblast to mature Ob and then to Os) from the same cell lineage, and to generate mature Os in the 
complete absence of extracellular matrix allowing these cells for unlimited biological applications (e.g. 
electrophysiology studies, etc). 
First, we reconfirmed our previous results demonstrating that the cultured cells represent well 
differentiated Os owing to the high levels of sclerostin. These cells also produce FGF23 at a consistently 
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higher degree when compared to other Ob cells. The maturation status of these cells was also confirmed by 
the specific IS for FGF23 which was confined to Os cells in mouse tibial bone tissue.  
It is still a matter of discussion whether AHSG is really produced in bone cells or is just captured by the bone 
microenvironment from its circulating pool [8-13]. More recently, Coen and co-workers [21] confirmed that 
AHSG mRNA and protein were expressed in some Os, in the Ob, though at a variable degree, and in the 
mineralized matrix in bone biopsies from haemodialysis patients.  
In our study, IHC in mouse tibial bone clearly demonstrated that AHSG was highly expressed in Os, while it 
was not evident in the majority of Ob. Furthermore, IHC performed on our cell cultures, confirmed the 
expression of AHSG in the Os which clearly increased over time, while Ob seem to produce a limited amount 
of this protein and its levels vanishing over time. These results are consistent with an in situ production of 
AHSG by bone cells, mainly by Os. This concept is reinforced by the demonstration that both AHSG gene 
(mRNA) and protein (WB) expression progressively and markedly increased in Os. These findings were 
paralleled by the demonstration of a consistent release of AHSG (ELISA) in the supernatant of both Os and 
Ob cultures, though again this was, by far, more evident in the former. So, our study confirms that AHSG is 
indeed produced by bone cells themselves, in particular by Os. Furthermore, our findings also demonstrate 
that AHSG production is variable both in Ob and in Os depending on the stage of cell maturation, with a 
progressive decrease and increase in the former and in the latter respectively. This finding might in part 
explain the discrepancies of the reported AHSG expression in bone cells between different studies.  
On the basis of these initial observations , we went on to investigate if there was a direct interaction 
between FGF23 and AHSG in our bone cell cultures.  
Preliminarily to any experimental study, we verified by Gene Cards® data base whether FGF23 and AHSG 
recognize the same or different transcription factors (TFs) in the same animal species as the one used in our 
experiments (mice). We found no evidence of common TF was albeit some direct and indirect TF 
interactions are reported [Gene Cards®]. 
Subsequently, we wondered if the addition of recombinant FGF23 or AHSG to cell supernatant could impact 
on FGF23 and/or AHSG production. For this purpose, we chose to investigate this issue in cultured Os at T4, 
which is the time when these cells initiate their production of both proteins. The addition of FGF23 induced 
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a consistent increase in both FGF23 itself and AHSG production, while AHSG addition was not followed by 
any variation of either protein expression. 
Though it is known that in bone cells [27] FGF23 production is stimulated by other FGFs, to the best of our 
knowledge this is the first report of an auto-stimulatory effect of FGF23. 
The meaning of this observation is currently unclear and deserves further specific studies. One striking 
finding is the unexpected stimulatory effect of FGF23 on AHSG. Thus, we studied the FGF23 effects on AHSG 
production challenging Os with recombinant FGF23 at several time points (day 4, 8, 12 in culture). The 
largest and most significant increase in AHSG production was confirmed only in Os cultured for 4 days, while 
this enhanced AHSG expression did not reach significance in cells cultured for 8 or 12 days. Interestingly, our 
study shows that at the same time of maximal AHSG production, Os start to change their shape, producing 
their dendritic processes. 
From these data we can argue that FGF23 could play a role in controlling AHSG production by Os, but this 
effect is probably active only in the first stages of Os maturation.  
There is no clear explanation for the meaning of such a stimulatory effect of FGF23 on AHSG production in 
bone cells. It could be just hypothesized that an autocrine and paracrine production of AHSG in the stage of 
Os maturation could facilitate the elongation of dendritic processes of these cells into the mineralizing 
matrix. 
Since the stimulus driven by high extracellular FGF23 concentration could be considered non-physiological 
or, at best, a rare condition, we moved on to verify if FGF23 overexpression in Os, which mimics the 
overproduction of this protein independently of the nature of the stimulating factor, could yield the same 
effects. Again, FGF23 overexpression in Os resulted in a significant increase of AHSG mRNA and protein 
expression in line to what previously observed after exogenous FGF23 addition to the cells. In parallel, an 
even more apparent elongation of Os overexpressing FGF23 was observed as compared to that seen in cells 
stimulated with exogenous FGF23. This finding is reminiscent of that already reported in Os stimulated by 
other FGFs [32, 33]. Since it is known that FGFs can also stimulate FGF23 production [34], it would be 
interesting to know if the shape modification of Os after FGFs stimulation is a direct or indirect, FGF23-
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mediated, effect.  
We then went on to explore if FGF23 silencing in Os, which mimics the reduced production from any stimuli, 
is also associated with changes in AHSG production. Our results show that in the Os downregulation of 
FGF23 mRNA was mirrored by a concomitant reduction in both AHSG mRNA and protein. Interestingly, 
FGF23 mRNA silencing was accompanied by a recovery in AHSG protein the rate of which was faster than 
that of FGF23 protein. These results strengthen the importance of the controlling effect of FGF23 on AHSG 
production in Os, which can be rapidly reverted with even minor changes in FGF23 levels.  
In a next series of experiments, we wondered if the observed effects of FGF23 were mediated by its 
recognized 4 receptors (FGFRs). First, we confirmed that our cultured cells express all the 4 classical FGFRs 
(FGFR1, FGFR2, FGFR3 and FGFR4), with FGFR1 appearing as the most expressed receptor, as already 
described in Os [35, 36]. 
Then we tested the effect of blocking FGFRs in all the above described experimental conditions. We chose 
FIIN1 as a FGFRs blocker, since its irreversible effects guarantee the stability of the block throughout the 
duration of the experimental conditions [35]. However, it is also worth underlining that the FIIN1 does not 
equally block all the 4 FGFRs, with its maximal effect having been reported on FGFR1 and the least on FGFR4 
[35, 36]. 
The addition of FIIN1 in control conditions did not produce any detectable effect on both FGF23 mRNA and 
protein, excluding any independent effect of the FGFRs block on the basal production of this hormone. Of 
relevance, the auto-stimulatory effect of FGF23 addition to the culture medium was completely abolished 
by FGFRs inhibition, strongly suggesting that this effect is completely mediated by FGFRs activity.  
It is acknowledged that FGF23 requires Klotho as an essential co-receptor, in order to for exert its effects 
[37, 38]. Since Klotho is not expressed in bone tissue, the exact pathway by which FGF23 can produce the 
observed effects in our bone cells remains to be clarified. We could hypothesize that, given the high 
concentrations of FGF23 achieved in the peri-cellular space of secreting cells, a nonspecific binding of FGFRs 
might occur, as has been suggested for the effects of this hormone on non-classical target organs in CKD 
patients, where very high peripheral concentrations of FGF23 are often observed. Alternatively, the 
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existence of other as yet undefined FGF23 receptors could be hypothesized.  
In contrast with the results on FGF23 production, FGFRs inhibition by itself translated into an unexpected 
upregulation of both AHSG mRNA and protein expression levels. Furthermore, when FGF23 stimulus was 
superimposed to the FGFRs inhibition an additional and consistent increase of AHSG mRNA and, to a lesser 
extent, of protein were observed. We have no clear explanation for these findings, though one can 
hypothesize that FIIN1 might have a direct effect on intracellular pathways controlling mRNA translational 
and/or post-translational mechanisms. Alternatively, we cannot exclude that FIIN1 might inhibit some other 
receptor(s), with a basic inhibitory effect on the AHSG production, which, when blocked, produces a 
stimulatory effect. However, neither of the two above hypotheses can explain the additional stimulatory 
effect of FGF23, in the presence of FGFRs blockage. We can only speculate that this additional stimulatory 
effect of FGF23 might be dependent on the activation of other yet unrecognized receptors. Alternatively it 
could also be hypothesized that, given that FIIN1 is not equally potent on all the 4 FGFRs, the stimulatory 
effect of FGF23 on AHSG production might be driven mainly by the FGFRs less inhibited by FIIN1 blockade. 
Further investigations are necessary to explore this issue further. 
The results of FGFRs inhibition on FGF23 overexpression effects, besides confirming the stimulatory effect of 
FGFRs block per se on AHSG production, demonstrate that the increase of FGF23 stimulates AHSG 
production in an FGFRs independent way, though this effect was not additive with FGFRs blockade per se as 
observed in the preceding experimental set.  
These results were paralleled by concomitant changes of AHSG promoter luciferase activity in these 
experimental conditions. Furthermore, WB analysis confirmed that FGF23 was present also at nuclear level, 
though to a lesser extent than in the cytoplasm. Even more relevant, we found that FGF23 and AHSG 
colocalized both at cytoplasm and nuclear level. Since these results were obtained with the duo-link 
techniques, which is positive for an intermolecular distance lower than 40nm, they indirectly suggest that 
these two proteins might be closely linked to each other. Overall, these results suggest that the described 
effects might be mediated by common genomic pathways. However, as previously mentioned, though no 
common TF at FGF23 and AHSG gene level have been reported, some indirect and direct interactions have 
been described. Therefore we cannot completely exclude that the described genomic effect of FGF23 on 
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AHSG promoter could be dependent on some direct interaction(s) utilizing shared pathways (e.g. PPAR-ʏ, 
CEBP-α, etĐͿ [GeŶeCaƌds® data ďase]. Clearly, this point deserves further investigation. 
 
4.CONCLUSIONS 
Our results strongly support the hypothesis that bone cells are a specific site for production of AHSG. 
Furthermore, our data also show that FGF23 is consistently involved in the control of AHSG production in 
the Os. These effects are mainly evident in the earlier stages of Os maturation, at least in our experimental 
settings, suggesting that bone AHSG production could play a role in counteracting and/or slowing the 
calcifying process within the bone mineral matrix, possibly facilitating the development of Os dendritic 
processes. Our study also suggests that the pathways for FGF23-dependent AHSG stimulation could be 
different when FGF23 acts as an autocrine factor (as it is mimicked by over-expression) or as a paracrine or 
hormonal stimulus (as shown by FGF23 addition into the medium). Though our results provide clear 
evidence for an FGFRs dependence of the auto stimulatory effect of FGF23 on its own production, they do 
not completely clarify the role of FGFRs in the FGF23-dependent AHSG production, an issue which 
mandates further investigations. Importantly, we also demonstrated a colocalization of FGF23 and AHSG at 
both cytoplasmic and nuclear level, suggesting also a close functional co-operation between these two 
molecules. A number of open issues ensue from these initial results. First, which are the specific roles, if 
any, of Os AHSG production in the bone; second, if these effects are limited to the bone tissue; third, if the 
FGF23 control of AHSG secretion, this could also affect circulating levels of this protein. Finally, due to the 
well-known involvement of both FGF23 and AHSG on CV and kidney functions, it would be worth knowing if 
and how much this newly described pathway might affect these organs and systems. Future studies are 
expected to give more insights into these issues. 
 
5.METHODS  
5.1.Cell culture conditions 
The MC3T3-E1 cell line, subclone 4 [39, 40] established from normal newborn mouse calvaria, was obtained 
from ATCC (LGC Standards S.r.l., Sesto San Giovanni, Milan, Italy). Cells were cultured in alpha-MEM medium 
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(Invitrogen, Milan, Italy), supplemented with 10% FBS (Sigma-Aldrich, Milan, Italy) and 1% 
streptomycin/penicillin (Sigma-Aldrich) in 75-cm2 flasks at a density of 400 000 cells/cm2. When cells 
reached 80% confluence, 50mg/ml ascorbic acid and 3mM glycerol 2-phosphate disodium salt hydrate 
(Sigma-Aldrich) were added to the medium. Medium was changed every other day. After 5 days of 
incubation with ascorbic acid-glycerol phosphate (AA/GP), the cells were tripsinised and replated at a 
density of 7000 cells/cm2 and cultured with basal medium plus AA/GP and 10uM retinoic acid (All Trans 
Retinoic Acid, ATRA, from Sigma-Aldrich) to obtain Os [24, 25, 41]. Alternatively  cells were cultured with 
basal medium plus AA/GP to obtain Ob. The cell populations were then studied at several time points, 
namely after 4, 8, 12 days of treatment.  
 
5.2.Immunohistochemistry and immunocytochemistry 
In this study ten male 45 days Balb/c mice (Charles River Italy, Inc. Lecco) were used. They were acclimatized 
for one week and water and basal diet were given ad libitum. All experiments were conducted in 
accordance to EU Directive 2010/63/EU for animal experiments. 
Calvaria tibial tissues were Isolated from 45 days old male mice by treatment with decalcifying solution (HCl 
37% / Formic acid 85% /distilled water) for 6 hours after which they were fixed in PFA 4% and embedded in 
paraffin. Dewaxed tissue sections were incubated with an rabbit anti-fibroblast growth factor 23 [Swiss Prot: 
Q9GZV9] (Santa Cruz Biotechnology, Heidelberg, Germany) and mouse anti-Alpha-2-HS-glycoprotein [Swiss 
Prot: P02765] (Abcam). Then IHC was performed on tissue sections using broad spectrum horse-radish 
peroxidase (HRP) polymer conjugated (Invitrogen). Four IHC cells were plated on Petri dishes or coverslips, 
where the cells were cultured in the same conditions as described above. For indirect immunofluorescence, 
cells were fixed in either 4% paraformaldehyde or cold acetone, depending on the primary antibody to be 
applied. After fixation, cells were incubated with the primary antibodies rabbit anti-FGF23 (Santa Cruz 
Biotechnology), and/or goat anti -Alpha-2-HS-glycoprotein [Swiss Prot: P02765] (Santa Cruz Biotechnology). 
As secondary, fluorescently-labelled antibodies, the following were used: Alexa Fluor 546 goat anti-rabbit 
IgG, Alexa Fluor 546 rabbit anti-goat IgG highly cross adsorbed (Invitrogen). 
Specificity of Ab labelling was demonstrated by the lack of staining after substituting the primary antibody 
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with control immunoglobulins (rabbit primary, mouse primary or goat Ab isotype  controls from Invitrogen). 
Slides were mounted with Fluorsave aqueous mounting medium (Calbiochem, Merck Chemicals Ltd., 
Nottingham, UK). Images were acquired by a Zeiss Axioscope 40FL microscope, equipped with AxioCam 
MRc5 digital videocamera and immunofluorescence apparatus (Carl Zeiss SpA, Arese, Mi, Italy), and 
recorded by AxioVision software 4.3 (Carl Zeiss SpA) or by Zeiss AxioObserver microscope equipped with 
high resolution digital videocamera (AxioCam, Zeiss) and Apotome system for structured illumination, and 
recorded by AxioVision software 4.8. 
 
5.3.ELISA tests 
AHSG levels in the supernatants were evaluated using a mouse ELISA AHSG kit (Uscnk, Houston, USA), 
aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶs. Protein expression was normalized using Janus Green Whole-
Cell Stain for 5 min. Careful washing was followed by addition of Elution Buffer and absorbance was read at 
615nm. Replicate background measurements were subtracted to all 450nm measures. The resulting 450nm 
values were then normalised to the 615nm values to account for differences in numbers of cells.  
The minimum detectable dose of mouse AHSG is typically less than 3.64 ng/ml. 
FGF23 levels in the supernatants were evaluated by mouse FGF23 C-terminal ELISA kit (Immutopics 
IŶteƌŶatioŶal, PaŶteĐ, ToƌiŶo, ItalǇͿ, aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶs. Mouse FGF23 has a 
sensivity of 4 pg/ml, intra-assay variation of 6.2% and inter assay variation of 5.9%. 
 
5.4.FGF23 and AHSG addition 
For studies of reciprocal effects of the addition of FGF23 and AHSG, Os 4 days were stimulated with 
400PG/mL of human recombinant FGF23 (Immunological Sciences, Roma, Italy) or with 500uG/mL of bovine 
serum AHSG (Sigma-Aldrich) for 24 hours. To determine the effects of recombinant FGF23 addition on AHSG 
expression, Os were stimulated with 400PG/mL of FGF23 for 24 hours at 4, 8, 12 days in culture, as 
specified. 
 
5.5.FGF23 overexpression 
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4 day Os were transfected with 10nM FGF23 mouse cDNA clone (ORF with GFP tagged C terminal) (OriGene 
Technologies Inc.MD, USA) using Lipofectamine2000 (Invitrogen) as transfecting agent. As control, non-
targeting cDNA clone was employed at the same concentration. Mouse FGF23 ORF cDNA clone with GFP 
tagged C terminal [Vector:pCMV6_AC-GFP, Tag: C-terminal TurboGFP, Sequence Data: [Genbank: 
NM_022657.3] .ORF Size:756bp, restriction sites: Sgfl-Mlul. 
 
5.6.FGF23 silencing 
4 day Os were transfected with 10nM siRNA duplexes using Lipofectamine2000 (Invitrogen) as the 
transfecting agent. Three commercially available siRNAs complementary to FGF23 mRNA were used (Sigma-
Aldrich). First sequence forward 5' GCU AUC ACC UAC AGA UCC A ϯ’ƌeǀeƌse pƌiŵeƌ 5’ UGG AUC UGU AGG 
UGA UAG C ϯ’, seĐoŶd seƋueŶĐe foƌǁaƌd pƌiŵeƌ 5’ CCA UAG GGA UGG UCA UGU A ϯ’ ƌeǀeƌse pƌiŵeƌ 5’ UAC 
AUG ACC AUC CCU AUG G ϯ’, Thiƌd seƋueŶĐe foƌǁaƌd pƌiŵeƌ 5’ CUC GAA GGU UCC UUU GUA U ϯ’, Reǀeƌse 
primer 5’ AUA CAA AGG AAC CUU CGA G ϯ’. As a control, non-targeting siRNAs were transfected at the same 
concentration. 
Transfection efficiency was determined by a fluorescently-tagged siRNA (Alexa-Fluor488; Amersham, Perkin 
Elmer, Waltham, MA). 
 
5.7.FGFRs inhibition 
The FGFRs inhibitor FIIN1 hydrochloride (1uM ,Tocris Biosciences, Bristol UK) was administered to Os 4 days 
for 24 hours. When used in the experiments with FGF23 stimulation, this inhibitor was added 6 hours 
before the addition of FGF23 and then together with FGF23. 
 
5.8.mRNA extraction, RT-PCR, and qRT-PCR 
Total RNA of Ob was extracted by Trizol (Invitrogen) and precipitated by chloroform-isopropilalcohol, 
washed in ethanol 75%, resuspended in nuclease free-water, then treated with DNase, resuspended, and 
quantified by spectrophotometry cDNA was prepared from 1ug RNA using the iScript Select cDNA Synthesis 
Kit and oligo(dt)20 primers (Bio-Rad, Segrate, Milan, Italy). While total RNA of Os was extracted by Aurum 
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total RNA mini kit (Biorad). 
Half of the mRNA extracted was used to evaluate AHSG expression, with the following primers: AHSG 
[Genbank: NM_001276450]: forward 5' CAC CGA ACT TAC CAC GAC CT 3'; reverse 5' ATG TCC TGT CTG CCA 
AAA CC 3'; and the other half was used to evaluate FGF23 expression, with the following primers: FGF23 
[Gene Bank: AF263536]: forward 5' GAT CCC CAC CTC AGT TCT CA 3'; reverse 5'CCG GAT AGG CTC TAG CAG 
TG 3'; data were normalized against the expression of GAPDH [Gene Bank: AY618199]: forward primer 5' 
GGT ATC GTG GAA GGA CTC ATG A 3'; reverse primer 5' GGC CAT CCA CAG TCT TCT G 3'. After assessment of 
primer specificity by RT-PCR, Real Time RT-PCR was run with iQ Sybr Green Supermix (Bio-Rad) on a MyIQ 
instrument (Bio-Rad), and data were analysed by the IQ5 Bio-Rad Software. For RT-PCR of FGFrs Os 4 days 
cDNA was amplified by PCR using primers FGFr1 [Gene Bank: NM_001079909]: forward primer 5' AGA CGG 
ACA ACA CCA AAC CA 3'; reverse primer 5' CCG CAT GCA GTT TCT TCT CC 3'; FGFr2 [Gene Bank: EF143340]: 
forward primer 5' CCG GGG AAT CGC TAG AGT TG 3'; reverse primer 5' GTG CAC CCC ATC CTT AGT CC 3'; 
FGFr3 [Gene Bank: NM_001163216]: forward primer 5' GTG GTG GCA GCT GTG ATA CT 3'; reverse primer 3' 
TTA AGC GGG AAG CGA GAG AC 5'; FGFr4 [Gene Bank: NM_008011]: forward primer 5' CTT GGG ACT TCA 
CAT CCC C 3'; reverse primer 5' AGA GCT GAT GCC CCT TTC AC 3'. A single amplicon of the correct size was 
generated with each primer set. Amplification conditions were PCR buffer with 2.5mM MgCl2, 200nM of 
each primer and fast Start Taq in the presence of 200nM dNTPs (Roche). Samples were amplified for 40 
cycles at 95°C for 30s, an annealing step at 60°C for 30s and an extension step at 72°C for 30s with a final 
extension at 72°C for 10min. PCR products were resolved with loading dye on 2% agarose gels containing 
5µl ethidium bromide in 0.5X Tris Borate EDTA (TBE) buffer alongside a low molecular weight DNA ladder 
and photographed under UV light using a GelDoc system (BioRad).  
 
5.9. Protein isolation and WB 
Cells were lysed by complete Lysis-M kit (Roche Monza, Italy). For the separation of cellular cytoplasm and 
nuclear fractions, a second lysis was performed using a solution containing 60ul of Lysis-M and 10ul of NaCl 
to obtain nuclear proteins.  
Protein lysates of cytoplasm or nucleus were then separated on a SDS-PAGE and transferred by 
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electroblotting on a PVDF membrane (ImmunBlot PVDF membrane, Bio-Rad). After blocking, each 
membrane was incubated with the primary antibodies, rabbit anti-FGF23 (Santa Cruz Biotechnology) and 
mouse anti-Fetuin-A (Abcam), followed by the HRP-conjugated secondary antibodies, and positive reaction 
products were identified by chemiluminescence (BM Chemiluminescence WBting Kit, Roche). Loading 
controls were conducted with antibodies directed against rabbit anti-cofilin [Swiss Prot: P18630] (Abcam). 
Images were digitally acquired by Chemidoc XRS instrument (Bio-Rad) and analyzed by Quantity One 
software (Bio-Rad).   
 
5.10.Gaussia Luciferase activity 
Control Os T4 were first transfected with Gluc-SEAP dual reporter clone pre-designed for AHSG promoter 
(Secrete-Pair Dual Luminescence and Gaussia Luciferase Reporter Assay kit, Genecopeia, Catalogue No.: 
MPRM17140-PG04) to study the basic AHSG promoter activities. Subsequently Os T4 were transfected with 
Gluc-SEAP dual reporter in combination with 10nM FGF23 mouse cDNA clone (ORF with C terminal GFP 
tagged, OriGene Technologies Inc.MD, described in 5.5 ) to analyze the effect of FGF23 overexpression on 
AHSG promoter activity. To determine the role of endogenous FGF23 we conducted the same two described 
above experiments in the presence of the FGFRs inhibitor FIIN1 (1µM). Every transfection was performed 
using Lipofectamine2000 (Invitrogen) as transfecting agent.  
Culture medium from transfected Os was collected to study the promoter activities at 24, 36, 48 hours after 
transfection. 
For the detection of the promoter activation, secreted luciferase was evaluated by bioluminescence 
analysed with spectrofluorometers FLX-Xenius (SAFAS Monaco). Seap (secreted alkaline phosphatase) was 
used as the internal control for signal normalization. 
Clone information 
Genbank: NM_013465, Description: Promoter clone for gene AHSG, Promoter length: 1241bp, Sequences 
length upstream of TSS: 1190bp, Sequence length downstream of TSS: 50bp, Vector: pEZX-PG04, Antibiotic: 
KaŶaŵǇĐiŶ, Repoƌteƌ GeŶe:GluĐ, CloŶiŶg Site at 5’: BgIII, EĐoRI, Whole Plasŵid size: 795Ϯďp, Staďle 
selection Marker: Puromycin, Tracking Gene: secreted alkaline phosphatase (SEAP), Cloning Site at 
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ϯ’:HiŶdIII. Suggested SeƋueŶĐiŶg Pƌiŵeƌs suggested: foƌǁaƌd pƌiŵeƌ 5' AGTTACTTAAGCTCGGGCCC ϯ’; 
ƌeǀeƌse pƌiŵeƌ 5' TTGTTCTCGGTGGGCTTGGC ϯ’.  
5.11.Protein interaction 
To detect AHSG -FGF23 interactions, Duolink (Sigma-Aldrich) in situ experiment was performed. Cells were 
fixed in cold acetone and incubated with rabbit anti-FGF23 primary antibody (Santa Cruz Biotechnology) 
and mouse anti-Fetuin-A (Abcam). Subsequently a second incubation with relative PLUS/MINUS PLA probe 
was performed and after amplification by ligation to visualize the interaction by immunofluorescence. 
Quantification of AHSG/FGF23 interactions was evaluated using IMAGE J program by following calculation: 
whole surface cells area - nucleus area. 
5.12.Statistical analyses  
Experiments were conducted on at least 3 replicates per each condition and time point. Data were 
eǆpƌessed as ŵeaŶ ± staŶdaƌd deǀiatioŶ ;SDͿ, StudeŶt’s t-test and ANOVA were applied to determine 
significance (p<0.05). For qRT-PCR, relative RNA abundance was determined using the comparative Ct 
method [42].  The fold-change (FC) calculated by the software, was evaluated according to the following 
formula: σFC = FC * ln2 * sqrt(σx2/nx+σy2/ny). Fold change error bars, represent the standard deviation (σ) 
of the fold change (FC).  
P ǀalues ǁeƌe ĐalĐulated ďased oŶ a StudeŶt’s t-test of the replicate 2^ (- Delta Ct) values for each gene in 
the control group and treatment groups, and p values <0.05 were considered significant.  
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